<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154829">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02060591</url>
  </required_header>
  <id_info>
    <org_study_id>14PAR01</org_study_id>
    <nct_id>NCT02060591</nct_id>
  </id_info>
  <brief_title>Comparison of Two Periarticular Injection Medications for Adjunctive Pain Management Following Total Knee Arthroplasty (TKA)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rothman Institute Orthopaedics</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rothman Institute Orthopaedics</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Investigators aim to study the efficacy of Exparel as compared to Marcaine, taking into
      account pain control, narcotic consumption, narcotic-related side effects, outcomes
      measures, and patient satisfaction. Moreover, the Investigators plan to perform cost-benefit
      analysis to evaluate whether use of Exparel decreases analgesic consumption, duration of
      hospital stay and the need for physical therapy postoperatively, therefore, offsetting its
      higher price in comparison with Marcaine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>2. Measure pain intensity score (pre and post-operatively) by visual analogue scale (VAS) method</measure>
    <time_frame>Within first 30 days post-operatively</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <condition>Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Exparel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Marcaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel</intervention_name>
    <arm_group_label>Exparel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marcaine</intervention_name>
    <arm_group_label>Marcaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All patients at least 18 years old who have primary unilateral TKA for osteoarthritis
        performed at Thomas Jefferson University Hospital.

        Exclusion Criteria:

          -  American Society of Anesthesiologist (ASA) score of 4 or higher

          -  Hepatic disease (contraindication for acetaminophen)

          -  Renal disease (contraindication for NSAIDs)

          -  Any contraindication for oxycodone, ketorolac, epinephrine, pregabalin, gabapentin,
             hydromorphone, Tramadol, morphine or other narcotics that are considered as part of
             routine postoperative pain control protocol

          -  Fibromyalgia

          -  Any contraindication for intrathecal opioid injection

          -  History of substance abuse during the last 2 years

          -  History of allergy to amide compounds

          -  Current consumption of monoaminoxidase (MAO) inhibitors and tricyclic antidepressant
             (TCA) medications

          -  Allergy to metabisulfite compounds

          -  Chronic use of opioid medications in the month prior to surgery (leads to opioid
             tolerance and/or opioid-induced hyperalgesia)

          -  Body weight&lt;50 Kg, BMI&gt;40 Kg/m2

          -  History of hypotension

          -  Patients with any surgery related complication in the first 4-6 weeks following TKA,
             such as infection or mechanical failure
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tiffany Morrison, MS, CCRP</last_name>
    <phone>267-339-7818</phone>
    <email>tiffany.morrison@rothmaninstitute.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rothman Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Morrison, MS, CCRP</last_name>
      <phone>267-339-7818</phone>
      <email>tiffany.morrison@rothmaninstitute.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>February 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
